Key clinical point: Patients with MS and COVID-19 could avoid infection reactivation and continue MS therapies during virus treatment.
Major finding: Only 17% of MS patients with COVID-19 required hospitalization.
Study details: Observational, prospective and clinical practice studies of a multidisciplinary protocol of 90 patients with MS and COVID-19 and real-world evaluation of 41 COVID-19-infected patients with MS.
Disclosures: Virginia Meca-Lallana, MD, has no relevant financial disclosures.
Meca-Lallana V, et al. MSVirtual2020. Abstracts P0025 and P0079.